Literature DB >> 26134937

Evaluation of Reported Malignant Transformation of Vestibular Schwannoma: De Novo and After Stereotactic Radiosurgery or Surgery.

Marlon M Maducdoc1, Yaser Ghavami, Mark E Linskey, Hamid R Djalilian.   

Abstract

OBJECTIVE: To critically analyze each reported case of malignant transformation of vestibular schwannoma (VS) after either stereotactic radiosurgery (SRS) or microsurgery (MS). DATA SOURCES: We searched the Pubmed/Medline database using the relevant key words vestibular schwannoma, acoustic neuroma, malignant, transformation, radiation, induced, stereotactic, radiosurgery, malignancy, GammaKnife, and CyberKnife and combinations thereof. STUDY SELECTION: Inclusion criteria for malignant transformation of VS after SRS included histopathology of initially benign VS, subsequent histopathology confirming malignant VS, reasonable latency period between malignancy and benign diagnoses. DATA EXTRACTION: A neurotologist and a skull base neurosurgeon independently assessed each case report for quality, entry, exclusion criteria, and comparability of extracted data. DATA SYNTHESIS: We calculated median age, latency times, and survival times for each case report.
RESULTS: Malignant transformation has been documented to occur after either SRS or MS. Eight cases were included that showed histopathologic evidence of malignant transformation after SRS and MS. Four cases of malignant transformation were included that demonstrated malignant transformation after MS only. Malignant transformation of VS can also occur de novo, and de novo malignant VSs are also encountered, which can confound a causal inference from either SRS or MS. Eighteen cases of primary malignant VS were included. Studies that were identified but not included in the review are summarized and tabulated. We found 12 studies of malignant transformation associated with NF2.
CONCLUSION: The potential mechanism leading to malignant transformation of VS seems more obvious for SRS and is less understood for MS. Given a low incidence of de novo malignant schwannoma, the possibility that these are spontaneous events in either setting cannot be ruled out. Risk of malignant transformation of VS after either SRS or MS is not zero; however, the magnitude of this risk is probably minimal based on the evidence from eight histopathologically confirmed cases.

Entities:  

Mesh:

Year:  2015        PMID: 26134937     DOI: 10.1097/MAO.0000000000000801

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  10 in total

Review 1.  [Radiosurgery and fractionated stereotactic radiotherapy of vestibular schwannoma].

Authors:  K Hamm; H-U Herold; G Surber; S Rosahl
Journal:  HNO       Date:  2017-05       Impact factor: 1.284

2.  CyberKnife for Treatment of Vestibular Schwannoma: A Meta-analysis.

Authors:  Hossein Mahboubi; Ronald Sahyouni; Omid Moshtaghi; Kent Tadokoro; Yaser Ghavami; Kasra Ziai; Harrison W Lin; Hamid R Djalilian
Journal:  Otolaryngol Head Neck Surg       Date:  2017-04-25       Impact factor: 3.497

3.  Clinical Results After Single-fraction Radiosurgery for 1,002 Vestibular Schwannomas.

Authors:  Paul Y Windisch; Joerg-Christian Tonn; Christoph Fürweger; Berndt Wowra; Markus Kufeld; Christian Schichor; Alexander Muacevic
Journal:  Cureus       Date:  2019-12-16

4.  [Malignization of vestibular schwannoma 13 years after radiation therapy].

Authors:  S Simmermacher; D Vordermark; T Kegel; C Strauss
Journal:  HNO       Date:  2017-09       Impact factor: 1.284

5.  Malignization of a vestibular schwannoma 13 years after radiation therapy.

Authors:  S Simmermacher; D Vordermark; T Kegel; C Strauss
Journal:  HNO       Date:  2017-08       Impact factor: 1.284

6.  Secondary malignancy following stereotactic radiosurgery for benign neurologic disease: A cohort study and review of the literature.

Authors:  Alexander D Sherry; Brian Bingham; Ellen Kim; Meredith Monsour; Guozhen Luo; Albert Attia; Lola B Chambless; Anthony J Cmelak
Journal:  J Radiosurg SBRT       Date:  2020

7.  EANO guideline on the diagnosis and treatment of vestibular schwannoma.

Authors:  Roland Goldbrunner; Michael Weller; Jean Regis; Morten Lund-Johansen; Pantelis Stavrinou; David Reuss; D Gareth Evans; Florence Lefranc; Kita Sallabanda; Andrea Falini; Patrick Axon; Olivier Sterkers; Laura Fariselli; Wolfgang Wick; Joerg-Christian Tonn
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

8.  Qu-Du-San-Jie decoction induces growth inhibition and vascular normalization in NF2-associated vestibular schwannoma.

Authors:  Jie Lin; Shi-Wei Li; Jing Zhang; Fu-Hao Chu; Cheng-Ze Li; Zhi-Xu Bie; Han-Lu Tang; Shan Gao; Ping Li; Meng-Ting Liao; Tian-Xi Xin; Fu Zhao; Pi-Nan Liu; Xia Ding
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

9.  Malignant Transformation in Vestibular Schwannoma: Clinical Study With Survival Analysis.

Authors:  Jiuhong Li; Qiguang Wang; Menglan Zhang; Guisheng Zhang; Si Zhang; Xuhui Hui
Journal:  Front Oncol       Date:  2021-04-14       Impact factor: 6.244

Review 10.  Efficacy and comorbidities of hypofractionated and single-dose radiosurgery for vestibular schwannomas: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Sergio Guadix; Anjile An; Drew Wright; Paul J Christos; Susan Pannullo; Andrew Brandmaier; Jonathan P S Knisely; Philip E Stieg; Rohan Ramakrishna
Journal:  Neurooncol Pract       Date:  2021-02-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.